

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2013

File No. 000-54598

**Stellar Biotechnologies Inc.**

(Name of Registrant)

**332 E. Scott Street, Port Hueneme, CA 93041**

(Address of principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

FORM 20-F      FORM 40-F \_\_\_\_\_

  X  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Stellar Biotechnologies Inc.  
(Registrant)

Dated: July 24, 2013

By: /s/ "Kathi Niffenegger"

Kathi Niffenegger  
Corporate Secretary

**Exhibits:**

99.1 News Release dated July 24, 2013

## **Stellar Biotechnologies Announces Joint Research on Clostridium Difficile Immunotherapy Accepted for Presentation**

**PORT HUENEME, CA, (July 24, 2013) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH),** announced today that a preclinical abstract on KLH-conjugate vaccine for Clostridium difficile infection ("C. diff") has been accepted for oral presentation at the 8<sup>th</sup> International Conference on the Molecular Biology and Pathogenesis of the Clostridia (ClostPath 8) to be held in Queensland, Australia October 22-26, 2013.

ClostPath is the preeminent scientific conference in the field of clostridial pathogenesis and covers the latest discoveries presented by leading international researchers.

The abstract titled "An Anti-C. difficile PSII Polysaccharide-KLH Conjugate Vaccine is Efficacious in Mice" is the result of preclinical research conducted together by scientists from Stellar and the University of Guelph (Ontario, Canada) ("Guelph"). The abstract highlights data that suggest that a PSII polysaccharide conjugated to Keyhole Limpet Hemocyanin (KLH) may be effective in stimulating immunity against Clostridium difficile infection.

Stellar and Guelph are working together under research and license option arrangements forged last year around the two groups' shared interest in developing novel, non-antibiotic methods to treat the devastating C. diff infection.

### **About Clostridium difficile**

Clostridium difficile is a major and growing cause of mortality and morbidity in hospitalized patients. Incidence of C. diff is at a record high in the U.S. with more than 330,000 cases reported in 2009. C. diff is a type of bacteria normally present in the intestine, but which can overgrow as a result of antibiotic use. It causes severe diarrhea and life-threatening intestinal conditions such as colitis. The cost of C. diff related treatment in the U.S. and Europe is estimated at more than \$7 billion annually.

### **About Stellar Biotechnologies, Inc.**

**Stellar Biotechnologies, Inc. (TSX-V: KLH) (U.S. OTC: SBOTF) (Frankfurt: RBT)** is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of [http://stellarbiotechnologies.com/investors/news\\_releases/](http://stellarbiotechnologies.com/investors/news_releases/)

Visit [www.StellarBiotech.com](http://www.StellarBiotech.com) and the KLH knowledge base [www.KLHSite.com](http://www.KLHSite.com).

### **Contacts:**

Herbert Chow, Ph.D., Chief Technology Officer  
hchow@stellarbiotech.com  
Phone +1 (805) 488-2800

Frank Oakes, Chairman  
investorrelations@stellarbiotech.com

### **Investor Relations:**

MZ Group  
Mark A. McPartland  
Senior Vice President  
Phone: +1 (212) 301-7130  
markmcp@mzgroup.us  
Web: [www.mzgroup.us](http://www.mzgroup.us)

### **Forward Looking Statements**

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

